Quarterly ResultMay 20, 2026, 07:02 AM
Evogene Q1 2026 Revenue $0.3M; Net Loss $5.9M
AI Summary
Evogene reported Q1 2026 financial results with revenues of $0.3 million, a significant decrease from the prior year, and an increased net loss of $5.9 million. The company highlighted strategic advancements, including expanding its pharma division with three new collaborations and progressing its ChemPass AI™ platform. While the herbicide development project with Bayer was discontinued, non-core subsidiaries Lavie Bio and Biomica are winding down operations and distributing dividends.
Key Highlights
- Q1 2026 Revenues: $0.3 million, a decrease from $2.3 million in Q1 2025.
- Q1 2026 Net Loss: $5.9 million, compared to a net loss of $3.0 million in Q1 2025.
- Cash, cash equivalents, and short-term bank deposits totaled $13.1 million as of March 31, 2026.
- Secured approximately $3.4 million gross proceeds from a warrant inducement agreement in February 2026.
- Expanded pharma division with three new collaborations: Systasy Biosciences, QUT, and Unravel Biosciences.
- Discontinued herbicide development project with Bayer due to unmet product criteria.
- Lavie Bio and Biomica subsidiaries approved dividends of $4.25 million and $2.7 million respectively.
- Q1 2026 operating loss: $3.2 million, compared to $3.0 million in Q1 2025.
Price Impact
More from EVGN